Enliven Therapeutics (ELVN) Interest Coverage Ratio (QoQ) (2020 - 2026)
Enliven Therapeutics (ELVN) Interest Coverage Ratio (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Enliven Therapeutics | 3.33 Bn | 2.88 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.70% |
| Dec 31, 2025 | -500.17% |
| Sep 30, 2025 | -4.88% |
| Jun 30, 2025 | 87.81% |
| Mar 31, 2025 | 37.53% |
| Dec 31, 2024 | -94.21% |
| Sep 30, 2024 | -8.74% |
| Jun 30, 2024 | 5.33% |
| Mar 31, 2024 | -47,909.57% |
| Dec 31, 2023 | 98.89% |
| Sep 30, 2023 | 67.54% |
| Jun 30, 2023 | 78.49% |
| Mar 31, 2023 | -157,820.06% |
| Dec 31, 2022 | 98.74% |
| Sep 30, 2022 | -104.42% |
| Jun 30, 2022 | 48.87% |
| Mar 31, 2022 | 87.28% |
| Dec 31, 2021 | -479.46% |
| Sep 30, 2021 | -1,466.02% |
| Jun 30, 2021 | -55.46% |